Nomination Committee appointed in respect of AGM 2020 in Alligator Bioscience AB
Lund, Sweden, November 13, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmace ...
Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
Preclinical Data Show that ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti ...
Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical Data to be presented at SITC 34th Annual Meeting
Lund, Sweden, November 6, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company will present new preclinic ...
Alligator Bioscience signs antibody agreement for Greater China with Biotheus Inc.
Lund, Sweden, August 20, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached wi ...
Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107)
Lund, Sweden, July 31, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide righ ...
Alligator Bioscience submits clinical trial application for ATOR-1017
Lund, Sweden, June 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Frontier – A Magazine about Alligator Bioscience and Immuno-oncology
Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...
Frontier – A Magazine about Alligator Bioscience and Immuno-oncology
Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...
Alligator Bioscience to present the ATOR-1015 Phase I study outline at ASCO
Lund, Sweden, May 16, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the outline of the ongoing Phase I study w ...